Effectiveness of maintenance electroconvulsive therapy-Evidence from modifications due to the COVID-19 pandemic.
COVID-19
continuation ECT
effectiveness
electroconvulsive therapy
maintenance ECT
Journal
Acta psychiatrica Scandinavica
ISSN: 1600-0447
Titre abrégé: Acta Psychiatr Scand
Pays: United States
ID NLM: 0370364
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
20
04
2021
received:
24
03
2021
accepted:
03
05
2021
pubmed:
8
5
2021
medline:
19
8
2021
entrez:
7
5
2021
Statut:
ppublish
Résumé
Continuation and maintenance ECT (c-/m-ECT) are effective in the prevention of relapse and recurrence of both affective and psychotic disorders. However, data are scarce concerning the trajectories of severe mental disorders after the end of c-/m-ECT. This prospective study investigates the clinical outcome of patients with versus without modifications of their c-/m-ECT schedules. In the context of the COVID-19 pandemic, ECT capacities were restricted at many clinics in early 2020. All patients receiving c-/m-ECT in March and April 2020 at our department (n = 53, unipolar depression, bipolar disorder, schizophrenia) were followed up for six months to investigate the impact of treatment modifications imposed by the pandemic. Based on individual decisions, c-/m-ECT was either (a) continued without modification, (b) continued with reduced frequency, or (c) discontinued. Both reduced frequency and discontinuation of c-/m-ECT were associated with significant clinical deterioration as measured by CGI-I (Clinical Global Impression Scale - Global Improvement) during the six-month follow-up when compared to the subgroup of patients without any treatment modification (p = 0.005, p = 0.011). Furthermore, patients with discontinued or reduced c-/m-ECT showed significantly higher rates of rehospitalizations (p = 0.028) and new acute courses of ECT (p = 0.018). Despite the limitations of a heterogeneous and relatively small sample, our study strongly corroborates the effectiveness of c-/m-ECT in a real-world population. Especially, patients with shorter time since index ECT seem to be at high risk for severe clinical deterioration in the case of treatment discontinuation or reduction.
Identifiants
pubmed: 33960406
doi: 10.1111/acps.13314
pmc: PMC8212113
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
238-245Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The Authors. Acta Psychiatrica Scandinavica published by John Wiley & Sons Ltd.
Références
Am J Psychiatry. 2015 Jan;172(1):52-8
pubmed: 25157964
Curr Neuropharmacol. 2017 Apr;15(3):359-371
pubmed: 28503107
Psychiatry Res. 2018 Jun;264:131-142
pubmed: 29631245
Biometrika. 1951 Jun;38(1-2):141-9
pubmed: 14848119
J ECT. 2020 Dec;36(4):265-271
pubmed: 32558761
J ECT. 2019 Sep;35(3):156-160
pubmed: 30973454
J ECT. 2019 Mar;35(1):14-20
pubmed: 29419559
Rev Psiquiatr Salud Ment (Engl Ed). 2020 Jan - Mar;13(1):5-10
pubmed: 31473181
J ECT. 2013 Jun;29(2):86-92
pubmed: 23303421
J ECT. 2008 Sep;24(3):191-4
pubmed: 18772702
Neuropsychobiology. 2011;64(3):129-40
pubmed: 21811083
Acta Psychiatr Scand. 2021 Apr;143(4):294-306
pubmed: 33506961
J ECT. 2004 Mar;20(1):13-20
pubmed: 15087991
Am J Geriatr Psychiatry. 2020 Nov;28(11):1133-1145
pubmed: 32863137
J ECT. 2012 Dec;28(4):225-8
pubmed: 22531209
Am J Psychiatry. 2016 Nov 1;173(11):1110-1118
pubmed: 27418381
Neuropsychopharmacology. 2013 Nov;38(12):2467-74
pubmed: 23774532
J ECT. 2020 Dec;36(4):226-228
pubmed: 32618743
Aust N Z J Psychiatry. 2018 May;52(5):415-424
pubmed: 29256252